Comment on

• Characterization of the Huntington intermediate CAG repeat expansion phenotype in PHAROS.

  Killoran A, Biglan KM, Jankovic J, Eberly S, Kayson E, Oakes D, Young AB, Shoulson I. Killoran A, et al. Neurology. 2013 May 28;80(22):2022-7. doi: 10.1212/WNL.0b013e318294b304. Epub 2013 Apr 26. Neurology. 2013. PMID: 23624566 Free PMC article.
• A role of mitochondrial complex II defects in genetic models of Huntington's disease expressing N-terminal fragments of mutant huntingtin.

  Damiano M, Diguet E, Malgorn C, D'Aurelio M, Galvan L, Petit F, Benhaim L, Guillermier M, Houitte D, Dufour N, Hantraye P, Canals JM, Alberch J, Delzescaux T, Déglon N, Beal MF, Brouillet E. Damiano M, et al. Hum Mol Genet. 2013 Oct 1;22(19):3869-82. doi: 10.1093/hmg/ddt242. Epub 2013 May 29. Hum Mol Genet. 2013. PMID: 23720495 Free PMC article.
• Glutathione peroxidase activity is neuroprotective in models of Huntington's disease.

  Mason RP, Casu M, Butler N, Breda C, Campesan S, Clapp J, Green EW, Dhulkhed D, Kyriacou CP, Giorgini F. Mason RP, et al. Nat Genet. 2013 Oct;45(10):1249-54. doi: 10.1038/ng.2732. Epub 2013 Aug 25. Nat Genet. 2013. PMID: 23974869 Free PMC article.